Geneva, Switzerland, May 12, 2022 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today announced the successful completion of a €7.7 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 2,678,251 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the “Offering”, respectively).
https://geneuro.ch/data/news/PR-GeNeuro-Closes-Financing-ENG-VF-May-12-2022.pdf